Effects of metabolic abnormalities, hyperandrogenemia and clomiphene on liver function parameters among Chinese women with polycystic ovary syndrome: results from a randomized controlled trial

Cai, Wei-Xiong; Gao, Jin-Ying; Luo, Xi; Ma, Hongli; Ge, Hang; Liu, N.; Xia, Qing; Wang, Y.; Han, Buwei; Wu, Xiaoke

doi:10.1007/s40618-018-0953-6

Cited by 7 publications

(4 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Increased expression levels of AMH, FSH, and LH are important as this may cause hyperandrogenemia in the body, and further damage to follicular function. 19 Current study also shows significantly higher serum levels of FSH, LH, and T in group B participants which indicate poor frontal ovarian function in these patients. However, there was no significant difference in E2, P, and PRL levels between groups A and B in terms of the pregnancy outcome, implantation, high-quality embryo, biochemical pregnancy, and clinical pregnancy rates were significantly better in the participants of group A. Bedenk et al 20 reported that the pathological increase of serum AMH level not only affects the ovarian function of pregnant women, but also damages the normal ovarian environment, resulting in poor oocyte and embryos quality, affecting normal pregnancy.…”

Section: Figure 2 Image Comparison Of Sex Hormone Levels In Patients Of Both Groups (A and B) (A) Follicle Stimulating Hormone (Fsh); (B)supporting

confidence: 48%

Anti-Mullerian hormone and associated pregnancy outcomes in females with polycystic ovary syndrome undergoing In vitro fertilization-embryo transfer

Cao

2021

BioMedica

View full text Add to dashboard Cite

Background and Objective: Polycystic ovary syndrome (PCOS) is the most common endocrine disorder among reproductive-aged women worldwide. Pregnancy in these women is highly affected by serum levels of Anti-Mullerian hormone (AMH). This study aimed to determine the association of serum AMH levels with pregnancy outcomes in females with polycystic ovary syndrome (PCOS) undergoing in vitro fertilization-embryo transfer (IVF-ET) Methods: A total of 200 PCOS patients undergoing IVF-ET in the Reproductive Medicine Center, Second People's Hospital of Jingmen, China were included. The patients were divided into two groups, A and B, based on their AMH levels. Serum sex hormones levels and pregnancy outcomes in terms of fertilization, cleavage, implantation, high quality embryo and biochemical  and clinical pregnancy rates were compared. Results: Mean age of the patients was 28.74±2.07 years in group A and 29.74±2.23 years in group B. Participants in group A had lower serum levels of follicle stimulating hormone (FSH), luteinizing hormone (LH), and testosterone (T) compared to group B. Also, better pregnancy outcomes and lower frequency of pregnancy complications were seen in the participants of group A (P<0.05). AMH serum levels showed high specificity and sensitivity in predicting IVF-ET clinical pregnancy in PCOS patients. Conclusion: Serum AMH levels in females with PCOS  predict  improved sex hormone profile and clinical pregnancy outcomes after IVF-ET

show abstract

Section: Figure 2 Image Comparison Of Sex Hormone Levels In Patients Of Both Groups (A and B) (A) Follicle Stimulating Hormone (Fsh); (B)supporting

confidence: 48%

Anti-Mullerian hormone and associated pregnancy outcomes in females with polycystic ovary syndrome undergoing In vitro fertilization-embryo transfer

Cao

2021

BioMedica

View full text Add to dashboard Cite

show abstract

“…Women with PCOS are more likely to have dyslipidemia and IR with compensatory hyperinsulinemia, T2D, metabolic syndrome, and cardiovascular problems [ 25 ]. Moreover, PCOS exhibits similar characteristics to NAFLD, such as IR, T2D, dyslipidemia, decreased sex hormone-binding globulin (SHBG), increased aminotransferase activity, and xanthine oxidase levels [ 26 ]. In particular, xanthine oxidase (XO) is a pro-oxidant enzyme found in the liver and is a molybdopterin-flavoprotein with two similar subunits (145 kDa) [ 27 ].…”

Section: Molecular Pathologymentioning

confidence: 99%

Dysregulated Liver Metabolism and Polycystic Ovarian Syndrome

Khan

Kim

et al. 2023

IJMS

View full text Add to dashboard Cite

A significant fraction of couples around the world suffer from polycystic ovarian syndrome (PCOS), a disease defined by the characteristics of enhanced androgen synthesis in ovarian theca cells, hyperandrogenemia, and ovarian dysfunction in women. Most of the clinically observable symptoms and altered blood biomarker levels in the patients indicate metabolic dysregulation and adaptive changes as the key underlying mechanisms. Since the liver is the metabolic hub of the body and is involved in steroid-hormonal detoxification, pathological changes in the liver may contribute to female endocrine disruption, potentially through the liver-to-ovary axis. Of particular interest are hyperglycemic challenges and the consequent changes in liver-secretory protein(s) and insulin sensitivity affecting the maturation of ovarian follicles, potentially leading to female infertility. The purpose of this review is to provide insight into emerging metabolic mechanisms underlying PCOS as the primary culprit, which promote its incidence and aggravation. Additionally, this review aims to summarize medications and new potential therapeutic approaches for the disease.

show abstract

“…Liver enzymes are elevated in PCOS women 95 . Metabolic abnormalities and high androgen levels in PCOS are linked to an increase in liver enzymes 96 . Insulin resistance, obesity, abdominal adiposity, and triglyceride are independent risk factors for NAFLD in PCOS women 97 .…”

Section: Non-alcoholic Fatty Liver Disease (Nafld)mentioning

confidence: 99%

Untitled

2019

IJPSR

View full text Add to dashboard Cite

Polycystic ovarian syndrome (PCOS) is a reproductive metabolic disorder affecting nearly 20% females, globally. Though Rotterdam consensus is widely used for assessment, it lacks definite diagnostic guidelines. Absence of PCOS guidelines for adolescent and post-menopausal women might be influencing the prevalence data. The prevalence varied with ethnicities and found high in urban than rural. Among women in reproductive age, the obese rural population also found vulnerable to PCOS, indicates the role of lifestyle factors in this syndrome. Erratic lifestyle predisposes to insulin resistance, or obesity leads to subsequent hyperinsulinemia and hyperandrogenemia. Also, genetic predisposition to hypothalamic pituitary gonadal (HPG) axis dysfunction and impaired ovarian steroidogenesis further influence the disorder. It dysregulates the oocyte maturation leading to polycystic ovaries, thereby, affects the normal ovarian functions. The environmental toxins which are endocrine disruptors further worsens the consequence of the disorder. Multiple factors make it difficult to decipher the independent pathway of pathogenesis. Apart from ovulatory and reproductive dysfunctions, PCOS have chronic metabolic consequences: cardiovascular disease (CVD), obesity, dyslipidemia, obstructive sleep apnoea, and non-fatty liver. These factors are interdependent and progressive. Since the studies have contradicting results; it's difficult to determine the impact of these consequences. Both non-obese and obese PCOS women found vulnerable to the same metabolic consequences. Hence, further long term, controlled studies are required to understand the exact pathogenesis and metabolic consequences both in obese and non-obese PCOS women. Moreover, both regional and multicentre cohort studies are required to understand the progression of disease in different ethnicities.

show abstract

Effects of metabolic abnormalities, hyperandrogenemia and clomiphene on liver function parameters among Chinese women with polycystic ovary syndrome: results from a randomized controlled trial

Cited by 7 publications

References 33 publications

Anti-Mullerian hormone and associated pregnancy outcomes in females with polycystic ovary syndrome undergoing In vitro fertilization-embryo transfer

Anti-Mullerian hormone and associated pregnancy outcomes in females with polycystic ovary syndrome undergoing In vitro fertilization-embryo transfer

Dysregulated Liver Metabolism and Polycystic Ovarian Syndrome

Untitled

Contact Info

Product

Resources

About